Natera rises as partners on late-stage cancer trial
BUZZ-Natera rises as partners on late-stage cancer trial ** Shares of genetic testing firm Natera NTRA.O rise 3.47% to $270.99
** Co says it has partnered with Aveta Biomics on a late-stage trial for an experimental oral therapy for head and neck cancer
** Aveta says the study will test APG-157, an experimental immunotherapy designed to help the body fight tumors
** Natera says its Signatera blood test will assess molecular residual disease and treatment response, and serve as a secondary endpoint
** Companies say the test will be used before, during and after treatment to monitor response
** Aveta notes the trial will enroll about 826 patients globally, with enrollment expected to begin in the second half of 2026
** Including session's move, Natera up about 17% YTD
(Reporting by Sahil Pandey in Bengaluru)
Recent news on Natera
See all newsBrief: FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay
Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers